TIGIT Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
TIGIT Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This TIGIT target evaluation report is generated based on structured data from PatSnap Target & Disease MCP and PatSnap Clinical Trials MCP. It shows how an AI agent can combine target biology, NSCLC context, clinical competition, and result evidence into a practical target evaluation page.
Explore PatSnap Life Sciences MCP Servers
Target
TIGIT
UniProt Q495A1
Target-linked drugs
136
136 with roll-up
NSCLC trials
77
TIGIT + NSCLC MCP query
Released results
56
Clinical result query
Executive View
TIGIT is a next-generation immune checkpoint with a focused but competitive NSCLC development landscape. The target is biologically attractive because it links T-cell and NK-cell suppression to PVR/CD155 and NECTIN2/CD112 signaling, but clinical differentiation remains the main challenge.
- Biology: TIGIT suppresses T-cell activation and can inhibit NK-cell cytotoxicity through ligand-driven inhibitory signaling.
- Clinical density: MCP returns 77 TIGIT + NSCLC trial records and 56 released result records.
- Competition: Development is concentrated around anti-TIGIT plus PD-(L)1 combinations.
- Strategy: Strong programs need patient-selection logic, combination rationale, and a clear benchmark against atezolizumab, durvalumab, pembrolizumab, and PD-L1 regimens.
Scorecard
Biology confidence: Medium-high
Clinical validation: Emerging
Competitive pressure: High
White-space potential: Selective
Biology and Disease Rationale
Target & Disease MCP identifies TIGIT as T cell immunoreceptor with Ig and ITIM domains. The retrieved profile describes TIGIT as an inhibitory receptor that suppresses immune responses through PVR/CD155 or NECTIN2/CD112 binding, downstream adapter recruitment, and inhibition of PI3K, MAPK, and NF-kappa-B signaling.
In NSCLC, TIGIT is evaluated mainly as a combination immune-checkpoint target. The disease context from Target & Disease MCP describes NSCLC as a heterogeneous disease group including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.
Explore PatSnap Life Sciences MCP Servers for AI agents
Selected Trial and Result Evidence
AZD6750
Recruiting Phase 1/2 study of AZD6750 in adults with selected advanced or metastatic solid tumors.
LIBRA
Recruiting Phase 2 study of novel combinations in NSCLC.
Tiragolumab adjuvant setting
Released Phase 3 record studying tiragolumab plus atezolizumab in resected PD-L1-positive NSCLC after adjuvant chemotherapy.
Stage III consolidation
Released Phase 3 record comparing atezolizumab plus tiragolumab with durvalumab after chemoradiation.
IP and R&D Recommendation
TIGIT IP review should focus on antibody sequence and Fc claims, combination regimens with PD-1 or PD-L1 blockade, biomarker selection, CD155/PVR biology, and line-of-therapy positioning in NSCLC.
Recommendation
TIGIT is worth monitoring and selectively entering, but not as an undifferentiated checkpoint antibody. The strongest opportunities are biomarker-defined combinations, differentiated bispecifics, and settings where PD-(L)1 alone leaves a clear efficacy gap.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
Data note: Target biology, disease profile, clinical trial counts, trial examples, and result evidence were generated from PatSnap Target & Disease MCP and PatSnap Clinical Trials MCP queries performed on July 9, 2026.
